Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

2.9K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
2.9K
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias01:25

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

957
Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
957
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

4.1K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
4.1K
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

615
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
615
Disturbances in Heart Rhythm01:29

Disturbances in Heart Rhythm

3.7K
Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
3.7K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

1.9K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

VIR-SAAF: a study protocol for a national decentralised randomised controlled trial of home-based sleep apnoea screening in patients with atrial fibrillation in Denmark.

BMJ open·2026
Same author

Cardiac remodelling and functional status after cardiac resynchronization therapy: comparison between de-novo implantation and upgrade from right ventricular pacing.

ESC heart failure·2026
Same author

Cyclooxygenase-1-Inhibition with Aspirin in Patients with Chronic Coronary Syndrome.

TH open : companion journal to thrombosis and haemostasis·2026
Same author

Prevention of depression in patients with atrial fibrillation using an online personalized intervention: The HOPE-AF feasibility study.

European journal of cardiovascular nursing·2026
Same author

The Danish Pacemaker and ICD Register: Review of Clinical and Research Potential.

Clinical epidemiology·2026
Same author

Obstructive sleep apnoea is associated with accelerated progression of diabetic kidney disease.

Diabetic medicine : a journal of the British Diabetic Association·2026

Related Experiment Video

Updated: Mar 30, 2026

Zebra II as A Novel System to Record Electrophysiological Signals in Zebrafish
06:15

Zebra II as A Novel System to Record Electrophysiological Signals in Zebrafish

Published on: August 16, 2024

926

[Treatment with amiodarone].

Kasper Adelborg, Eva Ebbehøj, Jens Cosedis Nielsen

    Ugeskrift for Laeger
    |November 11, 2015
    PubMed
    Summary
    This summary is machine-generated.

    Amiodarone effectively treats heart rhythm disorders but can cause adverse events. Regular, multidisciplinary monitoring is crucial for patients on this antiarrhythmic drug.

    More Related Videos

    The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
    23:33

    The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

    Published on: February 28, 2012

    84.7K
    Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
    28:13

    Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

    Published on: February 26, 2013

    34.3K

    Related Experiment Videos

    Last Updated: Mar 30, 2026

    Zebra II as A Novel System to Record Electrophysiological Signals in Zebrafish
    06:15

    Zebra II as A Novel System to Record Electrophysiological Signals in Zebrafish

    Published on: August 16, 2024

    926
    The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
    23:33

    The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

    Published on: February 28, 2012

    84.7K
    Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
    28:13

    Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

    Published on: February 26, 2013

    34.3K

    Area of Science:

    • Cardiology
    • Pharmacology

    Background:

    • Amiodarone is a widely used antiarrhythmic medication.
    • It is effective for both supraventricular and ventricular arrhythmias.
    • While generally safe, amiodarone is associated with various adverse events.

    Purpose of the Study:

    • To review the pharmacology of amiodarone.
    • To detail drug interactions, side effects, and adverse events.
    • To emphasize the need for systematic patient follow-up.

    Main Methods:

    • Literature review of amiodarone pharmacology.
    • Analysis of reported side and adverse effects.
    • Discussion of clinical management strategies.

    Main Results:

    • Amiodarone exhibits complex pharmacology and numerous drug interactions.
    • Most patients experience mild adverse events.
    • Serious, life-threatening adverse events can occur.

    Conclusions:

    • A comprehensive understanding of amiodarone's profile is essential.
    • Systematic, interdisciplinary follow-up is critical for managing outpatients.
    • Proactive monitoring can mitigate risks associated with amiodarone therapy.